Introduction: There is growing attention towards the possible long-term effect of COVID-19 on neuropsychiatric disorders. Methods: We tested the effect of a combined nutraceutical (Synaid) with known nootropic effects in 40 elderly patients with self-perceived cognitive decline after SARS-CoV-2 infection, treated at home or in hospital. Results: After 3 months of treatment, Synaid significantly improved functional status, MMSE and the main psychological disorders associated with mild cognitive impairment, both in patients previously cared for at home and in hospital because of SARS-CoV-2 infection. Conclusions: Synaid was well tolerated and effective in improving cognitive function and psychosocial parameters after SARS-CoV-2 infection.
Bove M, F.F. (2021). Effect of Synaid on cognitive functions and mood in elderly subjects with self-perceived loss of memory after COVID-19 infection. ARCHIVES OF MEDICAL SCIENCE, 17(6), 1797-1799 [10.5114/aoms/141502].
Effect of Synaid on cognitive functions and mood in elderly subjects with self-perceived loss of memory after COVID-19 infection
Bove MPrimo
Conceptualization
;Veronesi MInvestigation
;Cicero AFG
Ultimo
Supervision
2021
Abstract
Introduction: There is growing attention towards the possible long-term effect of COVID-19 on neuropsychiatric disorders. Methods: We tested the effect of a combined nutraceutical (Synaid) with known nootropic effects in 40 elderly patients with self-perceived cognitive decline after SARS-CoV-2 infection, treated at home or in hospital. Results: After 3 months of treatment, Synaid significantly improved functional status, MMSE and the main psychological disorders associated with mild cognitive impairment, both in patients previously cared for at home and in hospital because of SARS-CoV-2 infection. Conclusions: Synaid was well tolerated and effective in improving cognitive function and psychosocial parameters after SARS-CoV-2 infection.File | Dimensione | Formato | |
---|---|---|---|
Bove M_Effect of Synaid on cognitive functions_ArchMedSci_2021.pdf
accesso aperto
Tipo:
Versione (PDF) editoriale
Licenza:
Licenza per Accesso Aperto. Creative Commons Attribuzione - Non commerciale (CCBYNC)
Dimensione
49.93 kB
Formato
Adobe PDF
|
49.93 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.